SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vertex Pharmaceuticals (VRTX)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1169 64 0 VRTX
Emcee:  David Lieberman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1044I don't think he's changed all that much. He's just as much the kingrkrw-2/5/2009
1043Well said!! <<Boger's idea of resigning "on his own terms"rkrw-2/5/2009
1042I’ve read the book, which profiles Boger when he was in his late 30’s and early DewDiligence_on_SI-2/5/2009
1041BDM was a good read.mcbio-2/5/2009
1040You read The Billion Dollar Molecule. Borger's idea of resigning "on hkeokalani'nui-2/5/2009
1039"" To the contrary, he’s retiring on his own terms."' Yes, rMiljenko Zuanic12/5/2009
1038Highly unlikely that Boger was kicked out. To the contrary, he’s retiring on hisDewDiligence_on_SI-2/5/2009
1037finance.yahoo.com Finally, "One Old Sucker" is kicked out. Still, so Miljenko Zuanic12/5/2009
1036Info on MRK’s HCV protease inhibitor, MK-7009: Phase-2 trials: siliconinvestor.DewDiligence_on_SI-12/21/2008
1035Vertex Again Key Player at Hep C Meeting Adam Feuerstein 11/03/08 - 02:26 AM EDoc Bones-11/4/2008
1034New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotypescaram(o)uche-11/1/2008
1033AASLD presentation of PROVE-3 will not contain SVR data: siliconinvestor.comDewDiligence_on_SI-10/28/2008
1032Well FEV measurement has a fair bit of natural variance, so getting stat sig in Biomaven-10/21/2008
1031I believe the CF Foundation has funded a good part of this. Agree with your takerkrw-10/21/2008
10303-4% of the CF patient population, which is about 30,000 U.S. and 70,000 WW, hasidos-10/21/2008
1029I wouldn't guess VX-770 is a big part of Vertex' valuation, but I'm tuck-10/21/2008
1028ertex Announces Positive 28-Day Results for VX-770, an Oral Investigational Agentnsaf-10/20/2008
1027Vertex Falls on Cystic Fibrosis Drug Study Adam Feuerstein 10/20/08 - 01:03 PM Etnsaf-10/20/2008
1026Thanks, Jason....... appreciate your making that available. Anybody "ouscaram(o)uche-10/17/2008
1025Vertex Cystic Fibrosis Drug a Game-Changer Adam Feuerstein 10/16/08 - 10:50 AM Etnsaf-10/16/2008
1024JNJ Starts Phase-3 Telaprevir Study in <i>Second-Line</i> HCV silicDewDiligence_on_SI-10/15/2008
1023Good break tru with hepatite C: Vertex Reaffirms Prior Positive Study Results Fomlkr-9/24/2008
1022Vertex Pharmaceuticals Announces Correction to Abstract Data Published in Octobetnsaf-9/24/2008
1021The first patient has been dosed in the phase-3 Boceprevir trials: sec.govDewDiligence_on_SI-9/23/2008
1020Musings on today’s VRTX PR: siliconinvestor.comDewDiligence_on_SI-8/19/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News